| Overall | Follow-up outcome | |||
---|---|---|---|---|---|
Died from breast cancer | Died from other causes | Alive at the end of follow-up | P F-test | ||
Overall | n = 1,204 | n = 272 | n = 63 | n = 869 |  |
ER-positivea (%) | 58.0 | 42.5b | 67.0b | 61.8b | Â |
Among women with ER-positivea tumor | Â | Â | Â | Â | Â |
  % of tumor cell nuclei positively stained for ER | 64.7 (25.5) | 62.2 (27.0) | 65.6 (24.5) | 65.1 (25.2) | 0.53 |
  ER H-scorec | 100.8 (53.0) | 93.0 (52.9) | 104.5 (54.6) | 102.2 (52.9) | 0.22 |
  ER/PR/HER2 scored | –64.8 (40.6) | –49.9 (43.5) | –65.7 (34.7) | –67.9 (39.8) | <0.0001 |
White women | n = 681 | n = 131 | n = 24 | n = 526 |  |
ER-positivea (%) | 62.5b | 47.2b | 78.6b | 65.8b | Â |
Among women with ER-positivea tumor | Â | Â | Â | Â | Â |
  % of tumor cell nuclei positively stained for ER | 64.6 (25.9) | 58.0 (27.4) | 74.4 (18.1) | 65.2 (25.7) | 0.03 |
  ER H-scorec | 100.7 (53.2) | 82.3 (48.8) | 122.1 (44.9) | 102.8 (53.7) | 0.004 |
  ER/PR/HER2 scored | –67.6 (39.7) | –46.1 (44.7) | –78.8 (26.3) | –70.8 (38.2) | <0.0001 |
Black women | n = 523 | n = 141 | n = 39 | n = 343 |  |
ER-positivea (%) | 51.3b | 38.0b | 60.0b | 55.8b | Â |
Among women with ER-positivea tumor | Â | Â | Â | Â | Â |
  % of tumor cell nuclei positively stained for ER | 64.8 (24.9) | 67.2 (25.9) | 58.3 (26.9) | 65.0 (24.3) | 0.35 |
  ER H-scorec | 100.9 (52.8) | 105.5 (55.2) | 90.0 (58.4) | 101.0 (51.5) | 0.50 |
  ER/PR/HER2 scored | –60.3 (41.8) | –54.3 (42.1) | –54.8 (37.4) | –62.7 (42.1) | 0.35 |